Altimmune’s Pemvidutide Garners Mixed Reviews Following Phase II Obesity Data

Stock Down By 55%

22 Mar 2023

• By Ayisha Sharma

The US firm’s GLP-1/glucagon receptor agonist improved weight loss in a Phase II interim analysis, but concerns about drug safety and discontinuation have left investors cynical, even as analysts remain cautiously upbeat.

Weighing scales with measuring tape, fruits and dumbbells — Pemvidutide Was Combined With Diet And Exercise Measures • Source: Shutterstock

Altimmune Inc.’s pemvidutide has shown promising efficacy in a Phase II non-diabetic obesity trial but investors have been spooked by the rate of treatment discontinuations associated with adverse events, although analysts agreed safety concerns were overblown.

Pemvidutide is a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol related steatohepatitis (NASH). Its...